AMNOG

The Arzneimittelmarkt-Neuordnungsgesetz (AMNOG, English translation: "Pharmaceuticals Market Reorganisation Act") is a German law relating to the marketing of pharmaceutical products in Germany . It requires drug manufacturers to submit evidence to the Federal Joint Committee (Germany) that shows whether their new products have an added benefit compared to previous products.[1] It is credited with reducing the cost of healthcare in Germany.[2]

## References

1. ↑ "AMNOG - evaluation of new pharmaceutical". GKV-Spitzenverband. 2014. http://www.gkv-spitzenverband.de/english/statutory_health_insurance/amnog___evaluation_of_new_pharmaceutical/amnog___evaluation_of_new_pharmaceutical_1.jsp. Retrieved 27 May 2014.
2. ↑ Olga Khazan (22 May 2014). "Why Medicine Is Cheaper in Germany". The Atlantic. https://www.theatlantic.com/health/archive/2014/05/why-medicine-is-cheaper-in-germany/371418/.

## See also

* Healthcare in Germany
* Institute for Quality and Efficiency in Health Care

0.00

(0 votes)

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:AMNOG&oldid=3906610"